Triple-negative breast cancer (TNBC) is an aggressive subtype of BC in need for predictive biomarkers of response to neoadjuvant chemotherapy (NACT). We aimed to evaluate the predictive value of the TNBCtype-4 classifier in a population of TNBC treated with carboplatin and docetaxel (TCb).
Patients with stage I-III TNBC (ER and PR
RNAseq was available for 94 of the 121 patients enrolled. Patients included had a median age at diagnosis of 51 years (range 28-78), 69.1% had nodal involvement and 52.1% and 46.8% had stage II and III disease, respectively. pCR rate and pathological good response (pCR or RCBI) were 44.7% and 56.4%. TNBCtype-4 distribution was: 34.0% BL1, 20.2% BL2, 23.4% M and 14.9% LAR. An additional 7.4% were classified as ER-positive. BL1 was associated with a significant younger age at diagnosis and higher ki67 values. TNBCtype-4 showed a significant association with response to NACT (p = 0.027), even in multivariate analysis including tumor size and nodal status, with BL1 patients achieving the highest pCR rate (65.6%), followed by BL2 (47.4%). Conversely, LAR and ER-positive showed the lowest pCR rates, 21.4% and 14.3%. When compared to BL1, LAR and M subtypes had an OR of achieving a pCR of 0.14 and 0.30 respectively (p
TNBCtype-4 shows a significant predictive value of response in a TNBC cohort homogeneously treated with TCb, with BL1 and LAR displaying the best and worse responses to NACT respectively.
Clinical trial identification
Legal entity responsible for the study
Hospital General Universitario Gregorio Marañon
Institute of Health Carlos III (PI12-02684)
All authors have declared no conflicts of interest.